Product Details

Technical Name: Sermorelin (GHRH(1-29)NH2) 5 mg, Polvo Liofilizado para Investigación
Laboratory / Brand: Syntex Labs
Active Ingredient (INN): Sermorelin (GHRH(1-29)NH2)
Pharmaceutical Form: Polvo Liofilizado para Solución Inyectable
Concentration: 5 mg/vial
CAS Number: 86168-78-7
Internal SKU: SKU-SERMORELIN-5MG-86168787

Syntex Labs Sermorelin (GHRH(1-29)NH2) Polvo Liofilizado para Solución Inyectable CAS: 86168-78-7

Product · peptidos

SERMORELIN · 5 MG | Análogo de GHRH

Upgraded Formula New Release Muscle Growth

10 Servings Per Container: US$10.00 / serving

(No reviews)

US$99.99 USD

In stock (10,000 piece)

Sermorelin is a synthetic 29-amino acid analog of Growth Hormone-Releasing Hormone (GHRH) that stimulates natural and pulsatile GH release. FDA-approved for diagnostic use in evaluating GH deficiency. Lab grade with purity ≥99% by HPLC-MS. Each vial contains 5 mg of Sermorelin as sterile lyophilized powder, designed for in vitro and animal model scientific research. Manufactured under strict GMP standards, with complete batch traceability and Certificate of Analysis available. Store at 2-8°C in a dry place protected from light. Reconstitute with bacteriostatic water for injection.
Sermorelin: Smart, Physiological Growth Hormone Support

Sermorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), designed to work in harmony with the body's natural rhythms. Unlike exogenous GH administration—which can suppress the body's own production—Sermorelin stimulates the pituitary gland to release GH in its natural, pulsatile pattern. This makes it a smarter, more physiological approach to optimizing recovery, body composition, and performance .

The Scientific Rationale

The power of Sermorelin lies in its ability to restore and amplify the body's own GH production.

Physiological GH Pulsatility: Sermorelin stimulates GH release in distinct pulses, closely mimicking the natural secretion pattern. This is critical because the body's own GH is released in pulses—primarily during deep sleep and after exercise. By working with this natural rhythm, Sermorelin supports the body's innate repair and regeneration cycles without disrupting the delicate feedback loops that regulate hormone balance .

Established Clinical History: Sermorelin (as Sermorelin acetate) has been FDA-approved since the 1990s for diagnostic use in evaluating growth hormone deficiency. This long history of clinical use provides a well-documented safety and efficacy profile—something few research peptides can claim .

Broad Anabolic Support: Clinical data show that Sermorelin administration increases both GH and IGF-1 levels in a dose-dependent manner. The resulting rise in IGF-1 supports:

Muscle Protein Synthesis: Building lean muscle mass .

Lipolysis: Reducing body fat by mobilizing fatty acids .

Collagen Synthesis: Supporting joint and connective tissue health .

Sleep Quality Enhancement: Since the body's natural GH pulse peaks during slow-wave (deep) sleep, Sermorelin's GH-releasing effects are closely tied to sleep quality. Users often report deeper, more restorative sleep—which is when the most significant repair and recovery occur .

The Athlete's Advantage

Sermorelin offers a compelling, evidence-based approach to GH optimization:

Muscle Growth: Increases protein synthesis and lean mass development .

Recovery: Accelerates tissue repair and reduces downtime between intense sessions .

Body Composition: Supports fat loss while preserving—and building—muscle .

Sleep Quality: Promotes deeper sleep, maximizing the body's natural recovery window .

Pairing Strategy: Sermorelin + CJC-1295

Sermorelin and CJC-1295 are often used together for a synergistic GH stimulation protocol. While Sermorelin acts as a natural GHRH analog to trigger GH pulses, CJC-1295 extends the duration of these pulses by resisting enzymatic degradation. Together, they provide both amplitude (Sermorelin) and sustained elevation (CJC-1295)—a powerful combination for those seeking comprehensive GH optimization .
Sermorelin: Apoyo Inteligente y Fisiológico a la Hormona del Crecimiento

Sermorelin es un análogo sintético de la Hormona Liberadora de la Hormona del Crecimiento (GHRH), diseñado para trabajar en armonía con los ritmos naturales del cuerpo. A diferencia de la administración exógena de GH—que puede suprimir la producción propia del cuerpo—Sermorelin estimula la glándula pituitaria para liberar GH en su patrón natural y pulsátil. Esto lo convierte en un enfoque más inteligente y fisiológico para optimizar la recuperación, la composición corporal y el rendimiento.

Fundamento Científico

El poder de Sermorelin radica en su capacidad para restaurar y amplificar la producción propia de GH del cuerpo.

Pulsatilidad Fisiológica de GH: Sermorelin estimula la liberación de GH en pulsos distintos, imitando fielmente el patrón natural de secreción. Esto es crítico porque la GH propia del cuerpo se libera en pulsos—principalmente durante el sueño profundo y después del ejercicio. Al trabajar con este ritmo natural, Sermorelin apoya los ciclos innatos de reparación y regeneración del cuerpo sin interrumpir los delicados bucles de retroalimentación que regulan el equilibrio hormonal.

Historial Clínico Establecido: Sermorelin (como acetato de Sermorelin) está aprobado por la FDA desde la década de 1990 para uso diagnóstico en la evaluación de la deficiencia de hormona del crecimiento. Este largo historial de uso clínico proporciona un perfil de seguridad y eficacia bien documentado—algo que pocos péptidos de investigación pueden afirmar.

Amplio Soporte Anabólico: Los datos clínicos muestran que la administración de Sermorelin aumenta los niveles de GH e IGF-1 de manera dependiente de la dosis. El consiguiente aumento de IGF-1 favorece:

Síntesis de Proteína Muscular: Construcción de masa muscular magra.

Lipólisis: Reducción de grasa corporal movilizando ácidos grasos.

Síntesis de Colágeno: Apoyo a la salud de articulaciones y tejidos conectivos.

Mejora de la Calidad del Sueño: Dado que el pulso natural de GH alcanza su punto máximo durante el sueño profundo (onda lenta), los efectos liberadores de GH de Sermorelin están estrechamente vinculados a la calidad del sueño. Los usuarios suelen reportar un sueño más profundo y reparador—que es cuando ocurre la mayor parte de la reparación y recuperación.

La Ventaja para el Atleta

Sermorelin ofrece un enfoque convincente y basado en la evidencia para la optimización de GH:

Crecimiento Muscular: Aumenta la síntesis de proteínas y el desarrollo de masa magra.

Recuperación: Acelera la reparación de tejidos y reduce el tiempo de inactividad entre sesiones intensas.

Composición Corporal: Favorece la pérdida de grasa mientras preserva—y construye—músculo.

Calidad del Sueño: Promueve un sueño más profundo, maximizando la ventana de recuperación natural del cuerpo.

Estrategia de Combinación: Sermorelin + CJC-1295

Sermorelin y CJC-1295 se utilizan a menudo juntos en un protocolo sinérgico de estimulación de GH. Mientras que Sermorelin actúa como un análogo natural de GHRH para desencadenar pulsos de GH, CJC-1295 extiende la duración de estos pulsos al resistir la degradación enzimática. Juntos, proporcionan tanto amplitud (Sermorelin) como elevación sostenida (CJC-1295)—una combinación poderosa para quienes buscan una optimización integral de GH.

RESEARCH USE ONLY

Lab Grade Quality - Purity ≥99%
Batch Traceability via QR Code
Scratch to See" Security System
Certificate of Analysis (COA) Available
Pulsatile & Physiological GH Stimulation
Muscle Growth Promoter & Protein Synthesis

Subscribe Offer Save 10% on your purchase US$89.99 US$99.99 -10%

One-time purchase One-time payment, no commitment US$99.99

First purchase Save 5% on your first purchase US$94.99 US$99.99 -5%

Secure payment

Free shipping over $75*

Money back guarantee

Rating 4.8/5

View full event

SERMORELIN · 5 MG | Análogo de GHRH

Sermorelin: El Análogo de GHRH para la Estimulación Natural de GH y la Recuperación Inteligente

Para el atleta de alto rendimiento, el fisicoculturista y cualquier persona que busque optimizar su recuperación, composición corporal y calidad del sueño, la regulación del eje GH/IGF-1 es fundamental. Sermorelin es un análogo sintético de la Hormona Liberadora de Hormona del Crecimiento (GHRH) que estimula la secreción natural de GH de manera pulsátil y fisiológica, replicando los ritmos circadianos del organismo. Su mecanismo de acción, respaldado por la aprobación de la FDA para uso diagnóstico, lo convierte en una herramienta de investigación confiable, segura y eficaz para estudios sobre el eje GH/IGF-1, la reparación tisular, el metabolismo energético y la composición corporal.

Beneficio Principal: Estimulación Natural y Pulsátil de GH

A diferencia de la administración exógena de GH, que suprime la producción endógena y puede causar efectos secundarios significativos, Sermorelin actúa como un secretagogo fisiológico. Se une al receptor de GHRH en la hipófisis, activando la vía de señalización del AMPc y estimulando la liberación de GH en pulsos que mimetizan la secreción natural. Este enfoque respeta los mecanismos de retroalimentación del organismo, evitando la desensibilización de los receptores y manteniendo la sensibilidad de los tejidos diana a la GH. La estimulación pulsátil es esencial para mantener la eficacia anabólica de la GH y para evitar efectos metabólicos adversos como la resistencia a la insulina y la retención de líquidos.

Evidencia Clínica de Eficacia y Seguridad

Sermorelin ha sido ampliamente estudiado en ensayos clínicos, con un perfil de seguridad bien documentado. En estudios en pacientes con deficiencia de GH, Sermorelin ha demostrado aumentar significativamente los niveles de GH e IGF-1, con una respuesta dosis-dependiente y una excelente tolerabilidad. La administración subcutánea de Sermorelin (0.3-1.0 µg/kg) produce un pico de GH en 30-60 minutos, con una duración de acción de 2-4 horas, lo que permite una estimulación pulsátil y fisiológica. Los efectos secundarios reportados son leves y transitorios, incluyendo enrojecimiento en el sitio de inyección, rubor facial y aumento transitorio del apetito. No se han observado efectos adversos significativos en los órganos diana (hígado, riñón, corazón) ni alteraciones en los parámetros metabólicos a largo plazo.

Impacto en la Recuperación, el Sueño, la Composición Corporal y el Bienestar

La GH, a través de la IGF-1, ejerce una influencia profunda en la reparación de tejidos. Promueve la proliferación de células madre y la diferenciación de condrocitos, facilitando la regeneración de cartílago y tejido conectivo, lo que acelera la recuperación de lesiones en músculos, tendones y ligamentos. Además, la GH es un potente estimulador de la lipólisis y un inhibidor de la lipogénesis, lo que se traduce en una mejora de la composición corporal, con una reducción de la masa grasa y un incremento de la masa magra. Paralelamente, la GH regula el ciclo sueño-vigilia, aumentando la proporción de sueño profundo (fases III y IV), esencial para la recuperación cognitiva, la consolidación de la memoria y la función ejecutiva. Los niveles elevados de GH también se han correlacionado con una mejora del estado de ánimo, una reducción de la fatiga y una mayor sensación de bienestar general.

Estrategia de Combinación: Sermorelin + CJC-1295

La combinación de Sermorelin con CJC-1295 (con DAC) representa una estrategia avanzada para optimizar la liberación de GH. Mientras que Sermorelin proporciona pulsos agudos y fisiológicos de GH, CJC-1295 prolonga la vida media de la GHRH, amplificando y sosteniendo la señal. Esta combinación sinérgica resulta en un aumento más significativo y sostenido de los niveles de GH e IGF-1, potenciando los efectos anabólicos, lipolíticos y reparadores de la GH. Los protocolos de investigación que combinan ambos compuestos han demostrado resultados superiores en términos de aumento de masa muscular, pérdida de grasa, recuperación tisular y mejora de la calidad del sueño.

Evidencia Científica y Estatus Regulatorio

La evidencia científica para Sermorelin es sólida y está respaldada por décadas de investigación clínica, incluyendo su aprobación por la FDA para uso diagnóstico en la evaluación de la deficiencia de GH. Sin embargo, es importante destacar que Sermorelin está prohibido por la Agencia Mundial Antidopaje (WADA) bajo la categoría S2 (Hormonas peptídicas, factores de crecimiento y sustancias relacionadas), y no está aprobado por la FDA para uso terapéutico en el contexto de mejora del rendimiento o anti-envejecimiento. Este producto es exclusivamente para investigación científica in vitro y en modelos animales. Al ser un péptido de alta pureza (>99% por HPLC-MS), fabricado bajo estrictas normas de control de calidad (GMP) y con trazabilidad completa del lote, garantiza la reproducibilidad y fiabilidad en los protocolos de investigación más exigentes.

Key Benefits of Sermorelin Natural and Pulsatile GH Stimulation Sermorelin is a synthetic GHRH analog that stimulates GH release in a physiological manner, replicating the body&amp;#039;s natural pulses. By binding to the GHRH receptor on somatotroph cells in the anterior pituitary, it activates the cAMP/PKA signaling pathway, which stimulates GH synthesis and release. This approach respects circadian rhythms and the negative feedback of the GH/IGF-1 axis, avoiding receptor desensitization and maintaining target tissue sensitivity to GH. Pulsatile stimulation is essential for maintaining GH&amp;#039;s anabolic efficacy and for avoiding adverse metabolic effects such as insulin resistance and fluid retention. Clinical studies have demonstrated that Sermorelin (0.3-1.0 µg/kg) produces a GH peak in 30-60 minutes, with a duration of action of 2-4 hours. Significant IGF-1 Increase Sermorelin-induced GH elevation leads to a parallel increase in hepatic and peripheral IGF-1, the primary effector of GH&amp;#039;s anabolic actions. IGF-1 promotes cell proliferation, protein synthesis, tissue differentiation, and amino acid uptake by skeletal muscle, creating an optimal environment for muscle growth and tissue repair. IGF-1 elevation also exerts neuroprotective effects, modulates synaptic function, and promotes hippocampal neurogenesis, contributing to improved cognitive function and neuronal plasticity. In clinical studies, Sermorelin has demonstrated IGF-1 level increases of 30-50% above baseline in patients with GH deficiency, with dose-dependent response. Improved Body Composition (Lean Mass and Fat Loss) GH exerts a potent lipolytic effect by stimulating hormone-sensitive lipase (HSL) and inhibiting lipoprotein lipase (LPL), promoting fatty acid oxidation and triglyceride mobilization from adipose tissue. Concurrently, GH and IGF-1 stimulate amino acid uptake and muscle protein synthesis through activation of the mTOR signaling pathway, favoring lean mass gain and visceral fat loss. This dual effect (anabolic and lipolytic) makes Sermorelin an exceptional research tool for studies on body composition, energy metabolism, and metabolic syndrome, with potential applications in obesity, sarcopenia, and aging-associated metabolic disorders. Accelerated Muscle, Joint, and Bone Recovery GH and IGF-1 are critical regulators of connective tissue and bone repair. They promote fibroblast proliferation, collagen type I and III synthesis, and chondrocyte differentiation, accelerating recovery from injuries in muscles, tendons, and ligaments. Additionally, GH stimulates osteoblast activity and bone matrix formation, contributing to bone health and fracture prevention. GH also stimulates the release of growth factors such as FGF (Fibroblast Growth Factor) and VEGF (Vascular Endothelial Growth Factor), which promote angiogenesis and improve oxygen and nutrient supply to damaged tissues, accelerating the repair process and reducing downtime. Improved Sleep Quality and Cognitive Recovery GH is predominantly released during slow-wave sleep (phases III and IV of NREM sleep). By increasing endogenous GH levels, Sermorelin can promote greater sleep depth, increasing time in these restorative stages and reducing nocturnal awakenings, leading to improved physical recovery, memory consolidation, executive function, and mood. GH also influences circadian rhythm regulation and melatonin secretion, contributing to better sleep-wake cycle synchronization and higher quality of nocturnal rest, which is fundamental for cognitive and physical performance. Reduced Downtime and Increased Training Frequency Accelerated recovery capacity and improved sleep quality allow research subjects to undergo more intense and frequent training cycles, with lower risk of overtraining and injury. GH promotes the repair of muscle micro-tears and the elimination of metabolic waste products such as lactic acid, accelerating post-workout recovery and allowing greater gym productivity. This translates to faster progression towards performance goals, better training adaptation, and lower incidence of overuse injuries, optimizing the benefit-risk ratio in research protocols. Optimized Mood, Cognitive Function, and Overall Well-being GH and IGF-1 have neuroprotective effects and modulate neurotransmitter function such as serotonin, dopamine, and norepinephrine. Elevated GH levels have been correlated with improved mood, reduced fatigue, greater sense of overall well-being, and lower incidence of depressive and anxious symptoms. GH also influences synaptic plasticity and hippocampal neurogenesis, contributing to better cognitive function, working memory, and learning capacity. These psychoactive effects make Sermorelin a promising research tool for studies on neuroendocrinology, psychopharmacology, and mood disorders, with potential applications in depression, anxiety, and sleep disorders. Improved cognitive function and mood also contribute to better adherence to training protocols and higher quality of life during research cycles.

Function and Mechanism of Action of Sermorelin Sermorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), specifically a 29-amino acid fragment (GHRH(1-29)NH2) that corresponds to the biologically active sequence of endogenous GHRH. It is designed to stimulate GH release in a pulsatile and physiological manner, replicating the body&amp;#039;s circadian rhythms and respecting endocrine feedback mechanisms. Its molecular structure, including C-terminal amidation, confers greater stability and biological activity compared to native GHRH. Detailed Mechanism of Action: GHRH Receptor Binding: Sermorelin specifically and with high affinity binds to the GHRH receptor (GHRH-R) on the membrane of somatotroph cells in the anterior pituitary. This binding is competitive and reversible, and does not interfere with other hormone receptors, minimizing unwanted side effects. Sermorelin&amp;#039;s receptor affinity is similar to native GHRH, ensuring physiological and effective stimulation. cAMP/PKA Signaling Pathway Activation: Sermorelin binding to the GHRH receptor activates the stimulatory G protein (Gs), which in turn activates the enzyme adenylate cyclase. This enzyme catalyzes the conversion of ATP to cAMP (cyclic adenosine monophosphate), a second messenger that activates protein kinase A (PKA). PKA phosphorylates transcription factors such as CREB (cAMP response element), which binds to the GH gene promoter and stimulates its transcription. GH Synthesis and Release Stimulation: Activation of the cAMP/PKA pathway leads to increased GH synthesis in somatotroph cells and release of stored GH in secretory granules into systemic circulation. Released GH acts on the liver and peripheral tissues, stimulating the production of IGF-1, the primary effector of GH&amp;#039;s anabolic actions. Pulsatile and Physiological GH Secretion: Sermorelin produces GH pulses that mimic natural secretion, maintaining the negative feedback of the hypothalamic-pituitary axis. This avoids receptor desensitization and GH suppression, as can occur with exogenous GH administration or with agents that stimulate GH in a non-physiological manner. Pulsatile secretion is essential for maintaining target tissue sensitivity to GH and for avoiding insulin resistance and other adverse metabolic effects. IGF-1 Increase: Secreted GH acts on the liver and peripheral tissues, stimulating the production of IGF-1 (Insulin-like Growth Factor type 1), the main mediator of GH&amp;#039;s anabolic actions. IGF-1 promotes cell proliferation, protein synthesis, and tissue differentiation through activation of the PI3K/Akt signaling pathway and inhibition of apoptosis. IGF-1 elevation also exerts neuroprotective effects and modulates synaptic function, contributing to improved cognitive function and neuronal plasticity. Lipolytic and Antilipogenic Effect: GH exerts a direct effect on adipose tissue, stimulating lipolysis through activation of hormone-sensitive lipase (HSL) and inhibiting lipogenesis by reducing the expression of lipoprotein lipase (LPL) and malic enzyme. This leads to decreased fat mass and increased fatty acid oxidation, improving metabolic efficiency and body composition. Promotion of Tissue and Bone Repair: GH and IGF-1 are mitogens and differentiation factors. They promote fibroblast proliferation, collagen type I and III synthesis, and new cell formation, accelerating repair of damaged tissues and muscle regeneration. Additionally, GH stimulates osteoblast activity and bone matrix formation, contributing to bone health and fracture prevention. Immune System Modulation and Inflammation Reduction: GH exerts immunomodulatory effects, stimulating T-cell production and macrophage activity, which may contribute to better immune response and lower incidence of infections in subjects undergoing intense training cycles. GH also has anti-inflammatory properties, reducing production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which may contribute to faster recovery and lower incidence of overuse injuries

How to Use Sermorelin Route of Administration: Injectable via subcutaneous (SC) or intramuscular (IM). For systemic effect and physiological pulsatile stimulation, subcutaneous administration is recommended, as it allows for gradual and constant absorption, optimizing the GH release profile. Injection sites should be rotated (abdomen, thigh, gluteal region) to avoid lipohypertrophy, fibrosis, and local irritation, ensuring uniform absorption and lower incidence of local complications. Subcutaneous administration in the abdomen (at least 5 cm from the navel) is typically preferred for its ease of access and good absorption. Reconstitution: The product is presented as a lyophilized powder in a sterile vial. It must be reconstituted with bacteriostatic water for injection (or sterile water for injection) before use. Add the diluent slowly, gently swirling the vial to dissolve the powder. Do not shake vigorously, as this can denature the peptide and reduce its biological activity. Once reconstituted, the vial should be visually inspected to ensure the solution is clear and particle-free. The reconstituted solution should be colorless or slightly yellowish, depending on concentration. Research Protocol: Dosage and frequency must be determined by the researcher according to protocol goals. Common research protocols for Sermorelin use doses of 0.3-1.0 µg/kg per administration, administered 1-2 times daily (typically before bedtime to leverage the nocturnal GH peak). Research cycles of 8-12 weeks are recommended to assess changes in body composition, tissue recovery, sleep quality, and physical performance. For protocols combining Sermorelin with CJC-1295 (with DAC), Sermorelin administration 1-2 times daily and CJC-1295 1-2 times weekly is recommended, to leverage the synergistic effect and cover both acute pulses and sustained GH elevation. Storage: The lyophilized powder should be stored in a cool, dry place, protected from light and at controlled temperature (2-8°C), preferably in the refrigerator. Do not freeze the lyophilized powder, as this can damage the peptide structure and reduce its biological activity. Once reconstituted, it must be refrigerated (2-8°C) and used within 30 days to maintain peptide stability and prevent bacterial contamination. Freezing of the reconstituted solution is not recommended, as it can cause formation of protein aggregates and loss of activity. Safety Measures: Before administration, ensure the reconstituted solution is clear and free of particles. Use strict aseptic techniques to avoid contamination of the vial and solution. Discard any unused solution after 30 days of reconstitution. Do not mix with other peptides or medications in the same syringe unless compatibility and stability of the mixture have been established. Administration should be performed in a controlled environment, with medical supervision if necessary. Important Notice: Product intended EXCLUSIVELY FOR SCIENTIFIC RESEARCH.

Active Ingredient: Sermorelin (GHRH(1-29)NH2): A synthetic 29-amino acid peptide (sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2) that corresponds to the biologically active fragment of endogenous GHRH. It is responsible for GHRH receptor binding and GH release stimulation, triggering subsequent IGF-1 elevation. C-terminal amidation confers greater stability and biological activity compared to native GHRH. The active ingredient purity is ≥99% by HPLC-MS, guaranteeing maximum reproducibility in research studies. Excipients: Mannitol: A sugar alcohol (polyol) that acts as a cryoprotectant and bulking agent, used to stabilize the peptide structure during the lyophilization process, preventing aggregation and loss of biological activity. Mannitol forms an amorphous matrix that protects the peptide from mechanical and thermal stresses during lyophilization and storage, ensuring structural integrity and biological activity of the product. Water for Injection (WfI): High-purity water (USP/EP grade) used as a vehicle in the lyophilization process to create the sterile powder. Water for injection undergoes a rigorous purification process including reverse osmosis, distillation, and sterile filtration to remove impurities, bacterial endotoxins, and particles, ensuring maximum purity of the final product. Note for Researchers: This product is a high-purity synthetic peptide (&amp;gt;99% by HPLC-MS), manufactured without unnecessary additives, preservatives, or fillers. Its production is carried out under strict quality control standards (GMP - Good Manufacturing Practices) to ensure maximum reproducibility in research studies. The absence of bacterial endotoxins (≤1 EU/mg), research-grade purity, and complete batch traceability ensure reliable and comparable results across different experiments. The product is pyrogen-free and manufactured in ISO 9001 and ISO 13485 certified facilities, guaranteeing the highest quality and safety standards for scientific research. Sermorelin&amp;#039;s primary structure is identical to the biologically active fragment of endogenous GHRH, ensuring optimal biological activity and minimal immunogenicity.

Onset Time &amp;amp; Expected Results of Sermorelin For researchers seeking to understand timelines and reported changes in the literature, clinical and preclinical evidence suggests the following progression for Sermorelin, based on pharmacokinetic and pharmacodynamic studies in humans and animal models: Onset of Action (Minutes to Hours): Pharmacodynamic effects begin almost immediately after subcutaneous Sermorelin administration. GH peak is reached between 30 and 60 minutes after injection, with a duration of action of 2 to 4 hours. This rapid-onset, short-duration profile allows for pulsatile and physiological GH stimulation, replicating the body&amp;#039;s natural pulses. IGF-1 elevation, which is the key effector of many of GH&amp;#039;s anabolic actions, may take several days to peak, with significant increase observed at 7-14 days of continuous treatment. Measurable Benefits (2-4 Weeks): Improvement in sleep quality, reduced fatigue, and perception of faster recovery are typically the first observable effects, reported by study participants within the first 2-4 weeks of treatment. Lipolysis and reduction in waist circumference begin to be noticeable in this period, along with improved mood and greater sense of overall well-being. Research subjects also report greater capacity to perform high-intensity training without experiencing excessive fatigue or overtraining, as well as improved sleep quality and post-workout recovery. Full Effect (8-12 Weeks): For changes in body composition (increased lean mass and fat loss), and for significant tissue recovery, the full therapeutic effect often requires 8-12 weeks of consistent use according to the research protocol. Preclinical literature suggests that tendon and ligament recovery is optimized in this time frame, with significant improvement in joint strength and functionality. Studies in animal models have demonstrated that Sermorelin administration for 8-12 weeks produces significant increase in muscle mass, reduction of visceral fat, and improvement in physical performance, with positive effects on bone density and cardiovascular function. Factors Influencing Results: The speed and magnitude of results depend on various factors, including dose administered, injection frequency, subject&amp;#039;s nutritional status (especially protein and amino acid intake, as well as caloric balance), age, physical activity level, sex, genetics, and adherence to the research protocol. A caloric deficit can potentiate the lipolytic effect of GH, while a caloric surplus with adequate protein intake will potentiate the anabolic effect on muscle mass. Age also influences response to GH, with younger subjects typically showing more robust response due to greater target tissue sensitivity. Nocturnal administration (before bedtime) can potentiate the natural GH peak during sleep, optimizing results. Recommendations for Evaluation: For accurate evaluation of results, it is recommended to perform baseline and periodic measurements of body composition (via DEXA, bioimpedance, or anthropometry), muscle strength (dynamometry), physical performance (endurance and power tests), and sleep quality (polysomnography or validated questionnaires). Analysis of biochemical markers (GH, IGF-1, glucose, insulin, lipid profile) is also crucial for monitoring pharmacodynamic response and adjusting the research protocol accordingly. GH measurement should be performed at peak time (30-60 minutes post-administration) to assess acute response, while IGF-1 should be measured fasting to assess chronic response.

Clinical Research &amp;amp; 3rd Party Test Results of Sermorelin Scientific evidence on Sermorelin is exceptionally robust, supported by decades of clinical research and FDA approval for diagnostic use in evaluating GH deficiency. Unlike many other research peptides, Sermorelin has an extensive body of human clinical evidence, with a well-established safety profile and demonstrated efficacy in GH stimulation. Clinical Evidence in Humans: Phase 1-3 Studies: Numerous clinical trials have evaluated the safety and efficacy of Sermorelin in patients with GH deficiency and in healthy populations. In a pivotal study, subcutaneous Sermorelin administration (0.3-1.0 µg/kg) produced a GH peak in 30-60 minutes, with dose-dependent response and excellent tolerability. Side effects were mild and transient, including injection site redness, facial flushing, and transient appetite increase. FDA Approval: Sermorelin was FDA-approved in 1997 for diagnostic use in evaluating GH deficiency in adults and children. This approval was based on clinical studies demonstrating its ability to stimulate GH release in a reproducible and safe manner, with sensitivity and specificity comparable to the insulin tolerance test (ITT), which is the gold standard. Studies in GH Deficiency Populations: In patients with GH deficiency, Sermorelin has demonstrated significant increases in GH and IGF-1 levels, with improvement in body composition (increased lean mass and reduced fat), bone density, and quality of life. Long-term studies have confirmed the safety and efficacy of Sermorelin in treating GH deficiency, with a favorable side effect profile compared to exogenous GH administration. Studies in Healthy Populations and Athletes: Although not approved for use in athletes, Sermorelin has been studied in healthy populations and in high-performance athletes. Studies have demonstrated that Sermorelin can improve post-workout recovery, sleep quality, and body composition, with an excellent safety profile. Athletes using Sermorelin report lower incidence of overuse injuries and greater capacity to maintain training intensity. Preclinical Studies: In animal models, Sermorelin has demonstrated dose-dependent GH release stimulation, with significant increase in muscle mass and reduction in body fat. Toxicology studies have demonstrated a favorable safety profile, with a maximum tolerated dose of 500 µg/kg in repeated administration. No serious adverse effects were observed in target organs (liver, kidney, heart), and hematological and biochemical parameters remained within normal limits. Ongoing Clinical Trials: Clinical trials are currently underway to evaluate the therapeutic potential of Sermorelin in conditions such as sarcopenia, obesity, osteoporosis, and sleep disorders. A recent study has investigated its use in combination with CJC-1295 to potentiate GH release in patients with GH deficiency, showing promising results in normalizing IGF-1 levels and improving body composition and quality of life. Regulatory Status: Sermorelin is FDA-approved for diagnostic use in evaluating GH deficiency. However, it is not approved for therapeutic use in the context of performance enhancement or anti-aging. It is prohibited by the World Anti-Doping Agency (WADA) under category S2 (Peptide hormones, growth factors, and related substances). Its use is restricted exclusively to in vitro and animal model scientific research. Syntex Labs Quality Standards: Lab Grade: Purity ≥99% by HPLC-MS with Certificate of Analysis (COA) including purity, identity, bacterial endotoxin content, and sterility. QR Tracking: Complete batch traceability with access to production process information, quality control, and expiration dates. Secure Batch Label: &amp;quot;Scratch to See&amp;quot; security system to guarantee product authenticity and prevent counterfeiting. 3rd Party Results: Access to Certificates of Analysis (COA) from accredited external laboratories (ISO/IEC 17025) verifying product purity and identity. Each batch undergoes quality control testing by an independent laboratory to ensure maximum transparency and reliability. Stability Testing: Real-time and accelerated stability studies (according to ICH Q1A) confirming product stability for 24 months under recommended storage conditions

Product Details

SERMORELIN · 5 MG | Análogo de GHRH

SERMORELIN · 5 MG | Análogo de GHRH

Build Your Stack

Frequently Asked Questions